Saudi lung cancer management guidelines 2017

Jazieh, Abdul Rahman; Kattan, Khaled Al; Bamousa, Ahmed; Olayan, Ashwaq Al; Abdel-Warith, Abdel-Wahab A.; Ansari, Jawaher; Twairqi, Abdullah Al; Fayea, Turki Al; Saleh, Khalid Bin; Husaini, Hamed Al; Abdelhafiez, Nafisa; Mahrous, Mervat; Faris, M.; Omair, Ameen Al; Hebshi, Adnan Al; Shehri, Salem Al; Dayel, Fouad Al; Bamefleh, Hanaa; Khalbuss, Walid E.; Ghanem, Sarah Al; Loutfi, Shukri; Khankan, Azzam; Rujaib, Meshael Al; Ghamdi, Majed Al; Ibrahim, Nagwa; Swied, Abdulmonem; Kayait, Mohammad Al; Datario, Marie

doi:10.4103/atm.atm_92_17

Cited by 13 publications

(14 citation statements)

References 136 publications

(211 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The team set the objective of the guidelines and decided to follow the previously established format and same categories of level of evidence by the SLCA when published in the Saudi Lung Cancer Guidelines 2017. [ 6 ]…”

Section: Methodsmentioning

confidence: 99%

Saudi lung cancer prevention and screening guidelines

et al. 2018

Self Cite

View full text Add to dashboard Cite

BACKGROUND:While lung cancer is the leading cancer cause of death, it is largely preventable. Furthermore, early diagnosis enhances the chance of cure. Therefore, we developed guidelines for lung cancer prevention and early detection.METHODS:A multidisciplinary team of experts in lung cancer representing different health-care sectors was assembled based on the National Cancer Center request and in coordination with the Saudi Lung Cancer Association of Saudi Thoracic Society. The team reviewed various reliable international guidelines and the data and experience in the Kingdom and formulated guidelines that address the primary and secondary prevention approaches in lung cancer, including tobacco control, early diagnosis, and lung cancer screening.RESULTS:The team developed guidelines to assist healthcare professionals in the Kingdom manage the different aspects of lung cancer prevention. Primary prevention through tobacco control: the recommendations encourage all healthcare professionals in all practice settings to screen their patients for smoking and to provide counseling and if needed referral to smoking cessation programs for current smokers. For early diagnosis of patients with symptoms suspicions of lung cancer, it is expected standard of care to investigate, work up, and refer the patients appropriately. Mass screening of patients at high risk for developing lung cancer: the recommendations listed the program requirements, eligible patients, and algorithm to manage findings. However, the team does not recommend that national screening program be mandated or implemented for lung cancer at this stage until more data and studies provide stronger evidence to justify adopting a national program.CONCLUSIONS:Physicians can play an important role in preventing lung cancer by tobacco control and also detect lung cancer at earlier presentation. However, national mass screening programs require further study.

show abstract

Section: Methodsmentioning

confidence: 99%

Saudi lung cancer prevention and screening guidelines

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…As the half maximal inhibitory concentration (IC50) value can effectively distinguish the sensitivity or drug resistance of tumor cell lines to certain drugs (Jazieh et al, 2017;Qiu et al, 2019; Dasari and Tchounwou, 2014, we obtained 62 LUAD cell lines (containing CDDP sensitivity data) from the GDSC database for analysis. CDDP sensitivity, mRNA expression and mutation data were available for 61 LUAD cell lines, and the relevant data were used for downstream analysis ( Supplementary Table S1).…”

Section: Sensitivity Of Different Tumor Cell Lines and Lung Adenocarcmentioning

confidence: 99%

“…Lung cancer is the most common malignancy in the world (Bray et al, 2018), and LUAD is the most common histologic type of NSCLC (approximately 60%) (Chalela et al, 2017). Platinumbased chemotherapy is the standard first-line treatment for patients with advanced NSCLC (Jazieh et al, 2017). However, a considerable number of cases relapse after chemotherapy, resulting in a poor prognosis.…”

Section: Introductionmentioning

confidence: 99%

Identification of Mutations Related to Cisplatin-Resistance and Prognosis of Patients With Lung Adenocarcinoma

Liu

Fang

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Lung adenocarcinoma (LUAD) is the most common histologic type of nonsmall cell lung cancer (NSCLC; approximately 60%), and platinum-based chemotherapy is the cornerstone of the treatment for patients with LUAD. However, a considerable number of patients experience tumor recurrence after developing cisplatin (cisdiamminedichloroplatinum(II) or CDDP) resistance. Therefore, it is particularly important to screen primary CDDP-resistant LUAD patient populations, which can maximize the clinical benefits for these patients. Methods: Data for 61 LUAD cell lines were downloaded from the Genomics of Drug Sensitivity in Cancer (GDSC) database to screen for mutations related to CDDP susceptibility, and we conducted whole-exome sequencing (WES) of tumors from 45 LUAD patients from Zhujiang Hospital of Southern Medical University. Subsequently, the clinical prognostic value of these mutations was verified by using The Cancer Genome Atlas (TCGA)-LUAD cohort and our cohort (n 45). Results: Based on drug sensitivity data for the GDSC-LUAD cell lines and survival analysis of the cohorts TCGA-LUAD and Local-LUAD, we found only one gene (GREB1) with mutations related to decreased CDDP sensitivity as well as worse overall survival (OS) and progression-free survival (PFS) [OS: log-rank p 0.038, hazard ratio (HR; 95% confidence interval (95% CI)): 2.19 (0.73-6.55); PFS: log-rank p 0.001; HR: 4.65, 95% CI: 1.18-18.37]. The GREB1-mutant (GREB1-MT) group had a higher frequency of gene mutations. Additionally, gene set enrichment analysis (GSEA) and single-sample GSEA (ssGSEA) suggested reduced accumulation of intracellular drugs in the GREB1-MT group, in addition to increased drug efflux and enhanced DNA damage repair and intracellular detoxification. Conclusion: This study found that GREB1 mutations may mediate the primary resistance and clinical prognosis of LUAD patients undergoing treatment with CDDP. Further functional analysis showed that GREB1 mutations are related to the known mechanism of CDDP resistance. These results suggest that GREB1 mutations are potential biomarkers for screening of CDDP resistance among LUAD patients.

show abstract

“…Many international institutions established clinical practice guidelines for treating most types of cancers. [1][2][3] These guidelines are reviewed and updated periodically by a panel of experts in the field with a focus on the highest level of evidence (LOE). The highest LOE, level I, is achieved through phase III randomized clinical trials.…”

mentioning

confidence: 99%

Oncology research in Saudi Arabia over a 10-year period

Alghamdi

Alzahrani²,

Alhashemi³

et al. 2020

SMJ

View full text Add to dashboard Cite

Objectives: To assess the quality and quantity of Saudi publications in oncology over a 10-year period. Methods: A systematic PubMed search was conducted between January 2008 and December 2017 to retrieve all Saudi oncology publications. Data about the articles was collected. The level of evidence (LOE) was independently assessed by 2 authors. Two 5-year periods (2008-2012 and 2013-2017) were compared using the relevant parameters. Clinicaltrials.gov was also searched for all oncology trials registered in Saudi Arabia. Original Article Results: A total of 839 publications met our inclusion criteria. The most common type of research was case series, totaling 32% of all publications. Clinical trials formed less than 2% of the total. The LOE was I, II, III, and IV in 0.3%, 2.1%, 58.4%, and 39.3% of the included publications, respectively. The LOE was the same in the 2 periods. There were more publications in international journals (p=0.004), more international collaborations (p=0.001), and higher journal impact factors (p=0.037) in 2013-2017 than in 2008-2012. Only 76 registered clinical trials were found in the Clinicaltrials.gov registry. Conclusion: Despite an increase in the number of Saudi publications in the field of oncology over time, the LOE did not change. There were, however, some improvements in the international collaboration and journal impact factor, as well as an increase in the number of studies published in international journals. These observations call for a national strategy to improve oncology research in Saudi Arabia.

show abstract

Saudi lung cancer management guidelines 2017

Cited by 13 publications

References 136 publications

Saudi lung cancer prevention and screening guidelines

Saudi lung cancer prevention and screening guidelines

Identification of Mutations Related to Cisplatin-Resistance and Prognosis of Patients With Lung Adenocarcinoma

Oncology research in Saudi Arabia over a 10-year period

Contact Info

Product

Resources

About